Disease Landscape and Forecast Insights

Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK…

Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy…

  Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant…

Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin),…

Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of

The need for improved AD therapeutics is considerable; current treatment options are limited, and none can cease or even delay the inexorable cognitive and functional decline caused by the disease…

The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have…

The multiple myeloma market is becoming increasingly crowded. In 2015, several new, high-priced therapies have been approved for in the treatment of multiple myeloma, making this lucrative market…

Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios…

Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will…